ADS

ADS

Breaking News

Roche donates for education through ‘Roche Children’s Walk”

Bangkok, 21st June 2016 – Roche Thailand Ltd., led by Mr. Philippe Meyer, General Manager (1st from left) and Roche Diagnostics (Thailand) Ltd., led by Pichetpong Srisuwankul (1st from right), Managing Director, and employees held its annual ‘Roche Children’s Walk’ for 2016 and donated funds raised in support for deaf student’s education to Setsathian School for the Deaf under the Royal Patronage of His Royal highness Crown Prince Maha Vajiralongkorn, represented by Dr Panadda Wongchanta (2nd from left), Director. On this occasion, Roche executives and employees also planted homegrown vegetables in ‘Sufficient Herb Garden’ to support child development and learning.
 
‘Roche Children’s Walk’ is an annual global CSR event that marks its 13th year in 2016. With a concept of ‘Walking today for a better tomorrow’, the program emphasizes the business’ determination in supporting youth, the foundation of a country. Every year in June, Roche’s employees around the world will raise funds internally from various fundraising activities and donate the funds to both unprivileged children in Malawi, South Africa, and all countries where Roche has operations in, including Thailand. To date, ‘Roche Children’s Walk’ has supported the construction of seven orphan centers, served six million nutritious meals, trained 560 teachers a year and supported 17,000 children. Since 2003, over 150,000 Roche employees have walked at 141 sites, raising over 12.5 million CHF (456 million THB) to date.

About Roche
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people's lives. Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best possible way.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. Twenty-nine medicines developed by Roche are included in the World Health Organisation Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry seven years in a row by the Dow Jones Sustainability Indices.
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2015 employed more than 91,700 people worldwide. In 2015, Roche invested CHF 9.3 billion in R&D and posted sales of CHF 48.1 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.